Oxford Asset Management’s Ovid Therapeutics OVID Stock Holding History

Oxford Asset Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-127,117	Closed	-$528K	–	968
2019 Q4	$528K	Buy	127,117 +49,401	+64%	+$156K	0.01%	1207
2019 Q3	$252K	Buy	+77,716	New	+$177K	0.01%	1516
2019 Q2	–	Sell	-61,066	Closed	-$108K	–	1897
2019 Q1	$108K	Buy	61,066 +37,599	+160%	+$94K	﹤0.01%	1565
2018 Q4	$57K	Buy	+23,467	New	+$107K	﹤0.01%	1696
2018 Q2	–	Sell	-15,012	Closed	-$106K	–	1860
2018 Q1	$106K	Buy	15,012 +1,867	+14%	+$15.1K	﹤0.01%	1529
2017 Q4	$131K	Buy	+13,145	New	+$121K	﹤0.01%	1505
2017 Q3	–	Sell	-17,993	Closed	-$189K	–	1656
2017 Q2	$189K	Buy	+17,993	New	+$235K	﹤0.01%	1370

Other funds holding OVID

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oxford Asset Management's OVID Position: Q1 2020 in Review

Oxford Asset Management sold out of Ovid Therapeutics (OVID) in Q1 2020, closing a stake of 127,117 shares — an estimated $528K sold.

Oxford Asset Management first reported a position in OVID in Q2 2017 and held it in 7 quarters. The position peaked at $528K in Q4 2019. 57 funds tracked by Wall St. Rank hold OVID as of Q1 2020.

Oxford Asset Management reported no remaining Ovid Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 127,117 Ovid Therapeutics shares in Q1 2020, an estimated $528K.
Oxford Asset Management first reported a position in Ovid Therapeutics in Q2 2017 and held it in 7 quarters.
Oxford Asset Management's Ovid Therapeutics position peaked at $528K in Q4 2019.
57 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.